Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1111 Lincoln Road MIAMI BEACH FL 33139 |
Tel: | 1-917-5439932 |
Website: | https://www.pasithea.com |
IR: | See website |
Key People | ||
Lawrence Steinman Executive Chairman, Co-Founder | Tiago Reis Marques Chief Executive Officer, Director | Daniel H. Schneiderman Chief Financial Officer | Graeme Currie Chief Development Officer |
Business Overview |
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program. |
Financial Overview |
For the fiscal year ended 31 December 2023, Pasithea Therapeutics Corp revenues was not reported. Net loss before extraordinary items increased 32% to $15.5M. Higher net loss reflects Research and Development increase from $2.7M to $8.1M (expense), Ineffective G/L on Derivatives - Hedging decrease of 97% to $56K (income), Gain on forgiveness of accounts payable decrease from $11K (income) to $0K. |